C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes

Summary Non-specific markers of inflammation such as C-reactive protein (CRP) are associated statistically with an increased risk of atherosclerosis through mechanisms that have not yet been fully elucidated.We investigated the effects of CRP on several aspects of human monocyte biology, a cell type involved in the initiation and progression of atherosclerosis. Blood monocytes isolated from healthy men and premenopausal women (n=9/group) were exposed to purified CRP (25 μg/ml) for 12 hours. Changes in gene expression were analyzed using a custom-made array containing oligonucleotide sequences of 250 genes expressed by activated monocytes and confirmed by quantitative PCR. CRP increased significantly the expression of the cytokines interleukin (IL)-1α, IL-1β and IL-6, and the chemokines GRO-α, GRO-β and IL-8. CRP also displayed anti-inflammatory effects through upregulation of liver X receptor (LXR) α and activin receptor expression, and down-regulation of alpha 2-macroglobulin expression. Increased LXRα mRNA expression in both monocytes and the monocytic cell lineTHP-1 was associated with increased LXRα protein expression and nuclear translocation, as well as increased ABCA1 mRNA expression, a target gene of LXRα. Western Blot analysis revealed CRP-induced nuclear translocation of NF-κB and activation of p42/44, MAP and Akt kinases. CRP-induced LXRá mRNA expression was inhibited by anti-CD64 (FcγRI) antibodies and by p42/44 and PI3 kinase inhibitors. This hypothesis-generating study demonstrates that CRP modulates the expression of genes that contribute to both pro- and anti-inflammatory responses in human monocytes. Among these novel anti-inflammatory effects, we show clearly that CRP activates the LXRα pathway.

[1]  D. Sander,et al.  High-Sensitivity C-Reactive Protein Is Independently Associated With Early Carotid Artery Progression in Women But Not in Men: The INVADE Study , 2007, Stroke.

[2]  N. Suttorp,et al.  Adrenomedullin and endothelial barrier function , 2007, Thrombosis and Haemostasis.

[3]  J. Tegnér,et al.  Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia , 2007, Proceedings of the National Academy of Sciences.

[4]  Xian Wang,et al.  ROS and NF-κB but not LXR mediate IL-1β signaling for the downregulation of ATP-binding cassette transporter A1 , 2007 .

[5]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[6]  W. Hsueh,et al.  A Nuclear Receptor Corepressor–Dependent Pathway Mediates Suppression of Cytokine-Induced C-Reactive Protein Gene Expression by Liver X Receptor , 2006, Circulation research.

[7]  E. Paffen,et al.  C-reactive protein in atherosclerosis: A causal factor? , 2006, Cardiovascular research.

[8]  C. Mold,et al.  C-Reactive Protein Increases Cytokine Responses to Streptococcus pneumoniae through Interactions with Fcγ Receptors1 , 2006, The Journal of Immunology.

[9]  J. Filep,et al.  Loss of pentameric symmetry of C‐reactive protein induces interleukin‐8 production through peroxynitrite signaling in human neutrophils , 2005, Circulation research.

[10]  Arjun Deb,et al.  Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro: Implications of Contaminating Presence of Sodium Azide in Commercial Preparation , 2005, Circulation research.

[11]  J. Giddings,et al.  C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[12]  P. Reitsma,et al.  Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans , 2005, Circulation research.

[13]  T. Kodama,et al.  Expression of the LXR&agr; Protein in Human Atherosclerotic Lesions , 2005 .

[14]  J. Filep,et al.  Opposing Effects of C-Reactive Protein Isoforms on Shear-Induced Neutrophil-Platelet Adhesion and Neutrophil Aggregation in Whole Blood , 2004, Circulation.

[15]  J. McMurray,et al.  The clinical relevance of adrenomedullin: a promising profile? , 2004, Pharmacology & therapeutics.

[16]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[17]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[18]  V. Fuster,et al.  Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. , 2004, Circulation.

[19]  Sidney C. Smith,et al.  Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. , 2004, Circulation.

[20]  B. Joffe,et al.  High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. , 2004, The Journal of rheumatology.

[21]  Prapat Suriyaphol,et al.  Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts Before Detrimental Terminal Sequence , 2004, Circulation.

[22]  Yan Huang,et al.  C-Reactive Protein Stimulates MMP-1 Expression in U937 Histiocytes Through Fc&ggr;RII and Extracellular Signal-Regulated Kinase Pathway:: An Implication of CRP Involvement in Plaque Destabilization , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Paolo Raggi,et al.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[24]  S. Verma,et al.  Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II , 2003, Circulation.

[25]  S. Verma,et al.  New Markers of Inflammation and Endothelial Cell Activation: Part I , 2003, Circulation.

[26]  D. Herrington,et al.  Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. , 2003, Cardiovascular research.

[27]  Simon C Watkins,et al.  Transforming Growth Factor Blocks Tec Kinase Phosphorylation , Ca 2 Influx , and NFATc Translocation Causing Inhibition of T Cell Differentiation , 2003 .

[28]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[29]  D. Mangelsdorf,et al.  Liver X receptor signaling pathways in cardiovascular disease. , 2003, Molecular endocrinology.

[30]  Peter Tontonoz,et al.  Liver X Receptor-dependent Repression of Matrix Metalloproteinase-9 Expression in Macrophages* , 2003, The Journal of Biological Chemistry.

[31]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[32]  C. Mold,et al.  C-Reactive Protein Mediates Protection from Lipopolysaccharide Through Interactions With FcγR1 , 2002, The Journal of Immunology.

[33]  J. Van Damme,et al.  Macrophage inflammatory protein-1. , 2002, Cytokine & growth factor reviews.

[34]  A. Seeberger,et al.  Elevated cardiac troponin T in peritoneal dialysis patients is associated with CRP and predicts all-cause mortality and cardiac death. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  J. Witztum,et al.  Innate and acquired immunity in atherogenesis , 2002, Nature Medicine.

[36]  S. Barnum,et al.  Experimental Allergic Encephalomyelitis Is Inhibited in Transgenic Mice Expressing Human C-Reactive Protein1 , 2002, The Journal of Immunology.

[37]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[38]  R. Schmidt,et al.  Lack of specific receptors for C‐reactive protein on white blood cells , 2001, European journal of immunology.

[39]  J. Volanakis,et al.  Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.

[40]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[41]  E. Brown,et al.  Quantitative analysis of mRNA amplification by in vitro transcription. , 2001, Nucleic acids research.

[42]  J. Nilsson,et al.  Accumulation of LDL in Rat Arteries Is Associated With Activation of Tumor Necrosis Factor-&agr; Expression , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[43]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[44]  D. Bharadwaj,et al.  C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. , 2000, The Journal of clinical investigation.

[45]  F. Luscinskas,et al.  MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions , 1999, Nature.

[46]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[47]  T. Yamane,et al.  Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells. , 1998, Circulation.

[48]  J. Filep,et al.  Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. , 1997, The Journal of clinical investigation.

[49]  D. Xia,et al.  Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  H. Nagase Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.

[51]  H. Tilg,et al.  Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells , 1993, The Journal of experimental medicine.

[52]  Irving Kushner,et al.  C‐reactive protein increases production of IL‐1α, IL‐1β, and TNF‐α, and expression of mRNA by human alveolar macrophages , 1993, Journal of Leukocyte Biology.

[53]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[54]  Andrew W. Taylor,et al.  Effect of alpha-2-macroglobulin on cytokine-mediated human C-reactive protein production , 1991, Inflammation.

[55]  J. Boudreaux,et al.  Nuclear localization of liver X receptor alpha and beta is differentially regulated. , 2007, Journal of cellular biochemistry.

[56]  Xian Wang,et al.  ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. , 2007, American journal of physiology. Cell physiology.

[57]  J. Boudreaux,et al.  Nuclear localization of liver X receptor α and β is differentially regulated , 2007 .

[58]  T. Kodama,et al.  Expression of the LXRalpha protein in human atherosclerotic lesions. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[59]  Peter Tontonoz,et al.  Reciprocal regulation of inflammation and lipid metabolism by liver X receptors , 2003, Nature Medicine.

[60]  C. Mold,et al.  C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. , 2002, Journal of immunology.

[61]  I. Splichal,et al.  Induction of inflammatory cytokines by Nocardia fractions. , 1993, Folia biologica.